Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis

Robert W Foley; Nathan T Tagg; Matthew K Schindler; Kaylan M Fenton; Daniel S Reich; Irene Cortese; Ellen M Mowry

doi:10.1177/1352458517702533

Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis

Mult Scler. 2017 Sep;23(10):1424-1427. doi: 10.1177/1352458517702533. Epub 2017 Jun 22.

Authors

Robert W Foley¹, Nathan T Tagg², Matthew K Schindler², Kaylan M Fenton³, Daniel S Reich⁴, Irene Cortese², Ellen M Mowry³

Affiliations

¹ Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; School of Medicine, University College Dublin, Dublin, Ireland.
² Division of Neuroimmunology and Neurovirology, National Institute of Neurological Disorder and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.
³ Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
⁴ Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA/Division of Neuroimmunology and Neurovirology, National Institute of Neurological Disorder and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.

Abstract

Natalizumab is a recombinant humanized monoclonal antibody that decreases T-cell migration into the central nervous system (CNS) through α4 integrin:adhesion-molecule inhibition, thereby increasing the risk for opportunistic CNS infection. Herein, we report a case of infusion-associated aseptic meningitis in a patient receiving natalizumab.

Keywords: MRI; Multiple sclerosis; disease-modifying therapies; natalizumab.

Publication types

Case Reports

MeSH terms

Adult
Female
Humans
Immunologic Factors / adverse effects*
Meningitis, Aseptic / chemically induced*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Natalizumab / adverse effects*
Recurrence

Substances

Immunologic Factors
Natalizumab

Grants and funding

ZIA NS003119-07/Intramural NIH HHS/United States